Limitations of quantiferon-TB gold assay for screening of psoriasis patients prior to anti-tumour necrotic factor treatment

Alessandra BuaDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy; Correspondence[email protected]

Stefania ZanettiDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy;

Maria Francesca PeigottuDermatology Unit, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy;

Maria Antonetta MontesuDermatology Unit, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy;

Paola MolicottiDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy;

References

Bartalesi F, Spinicci M, Mencarini J, et al. The role of quantiferon-TB in-tube in the diagnosis and treatment monitoring of active tuberculosis. Infect Dis (London). 2017;49:474–477.
PubMed Web of Science ®Google Scholar
Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–509.
PubMed Web of Science ®Google Scholar
Gisondi P, Pezzolo E, Lo Cascio G, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis candidate to biological therapy. Br J Dermatol. 2014;171:884–890.
PubMed Web of Science ®Google Scholar
Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON(®)-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011;164:553–559.
PubMed Web of Science ®Google Scholar
Sánchez-Moya AI, García-Doval I, Carretero G, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2013;27:1366–1374.
PubMed Web of Science ®Google Scholar
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
PubMed Web of Science ®Google Scholar
Choe YB, Hwang YJ, Hahn HJ, et al. A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis. Mediators Inflamm. 2003;12:309–313.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Limitations of quantiferon-TB gold assay for screening of psoriasis patients prior to anti-tumour necrotic factor treatment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Limitations of quantiferon-TB gold assay for screening of psoriasis patients prior to anti-tumour necrotic factor treatment

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date